NASDAQ:VRAYViewray Stock Price, Forecast & News

$2.65

-0.08 (-2.93 %)

(As of 04/10/2020 06:00 AM ET)

Add

Compare

Today's Range

$2.52

Now: $2.65▼

$2.77

50-Day Range

$1.35

MA: $2.42▼

$3.37

52-Week Range

$1.11

Now: $2.65▼

$9.76

Volume1.51 million shs

Average Volume2.75 million shs

Market Capitalization$390.72 million

P/E RatioN/A

Dividend YieldN/A

Beta1.18

ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Viewray has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 7 buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $5.61, Viewray has a potential upside of 111.7% from its current price of $2.65.
Amount of Analyst Coverage
Viewray has only been the subject of 4 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Viewray has received 269 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Viewray has received 211 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Viewray has received 56.04% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote “Outperform” if you believe VRAY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Viewray does not currently pay a dividend.
Dividend Growth
Viewray does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Viewray insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 15.48% of the stock of Viewray is held by insiders.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Viewray are expected to decrease by -8.75% in the coming year, from ($0.80) to ($0.73) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Viewray is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Viewray is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Viewray has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.22 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Electromedical equipment

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VRAY

Previous Symbol

CUSIPN/A

CIK1597313

Webhttp://www.viewray.com/

Phone440-703-3210

Debt

Debt-to-Equity Ratio0.25

Current Ratio5.28

Quick Ratio4.35

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$87.78 million

Price / Sales4.45

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.47 per share

Price / Book1.80

Profitability

EPS (Most Recent Fiscal Year)($1.18)

Net Income$-120,200,000.00

Net Margins-136.93%

Return on Equity-81.70%

Return on Assets-41.98%

Miscellaneous

EmployeesN/A

Outstanding Shares147,440,000

Market Cap$390.72 million

Next Earnings Date5/7/2020 (Estimated)

OptionableOptionable

Receive VRAY News and Ratings via Email

Sign-up to receive the latest news and ratings for VRAY and its competitors with MarketBeat's FREE daily newsletter.

Viewray (NASDAQ:VRAY) Frequently Asked Questions

How has Viewray's stock been impacted by COVID-19 (Coronavirus)?

Viewray's stock was trading at $1.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VRAY stock has increased by 56.8% and is now trading at $2.65. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Viewray?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Viewray.

When is Viewray's next earnings date?

Viewray is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Viewray.

How were Viewray's earnings last quarter?

Viewray Inc (NASDAQ:VRAY) released its quarterly earnings results on Thursday, March, 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.06. The company earned $16.47 million during the quarter, compared to analyst estimates of $17.05 million. Viewray had a negative return on equity of 81.70% and a negative net margin of 136.93%. View Viewray's earnings history.

What guidance has Viewray issued on next quarter's earnings?

Viewray updated its FY 2020 After-Hours earnings guidance on Thursday, March, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $58-95 million, compared to the consensus revenue estimate of $110.15 million.

What price target have analysts set for VRAY?

10 analysts have issued 12-month price objectives for Viewray's shares. Their forecasts range from $2.00 to $8.00. On average, they anticipate Viewray's share price to reach $5.61 in the next year. This suggests a possible upside of 111.7% from the stock's current price. View analysts' price targets for Viewray.

Has Viewray been receiving favorable news coverage?

Media stories about VRAY stock have trended very negative on Friday, InfoTrie reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Viewray earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutViewray.

Who are some of Viewray's key competitors?

Some companies that are related to Viewray include CONMED (CNMD), Natus Medical (NTUS), InMode (INMD), Zynex (ZYXI), AxoGen (AXGN), TransMedics Group (TMDX), Semler Scientific (SMLR), Stereotaxis (STXS), BioLife Solutions (BLFS), Cutera (CUTR), Rockwell Medical (RMTI), BioSig Technologies (BSGM), Soleno Therapeutics (SLNO), Fonar (FONR) and Edap Tms (EDAP).

What other stocks do shareholders of Viewray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Amarin (AMRN), Alibaba Group (BABA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Pieris Pharmaceuticals (PIRS), Zynerba Pharmaceuticals (ZYNE), Anavex Life Sciences (AVXL) and Cara Therapeutics (CARA).

When did Viewray IPO?

(VRAY) raised $52 million in an initial public offering (IPO) on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

What is Viewray's stock symbol?

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

How do I buy shares of Viewray?

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Viewray's stock price today?

One share of VRAY stock can currently be purchased for approximately $2.65.

How big of a company is Viewray?

Viewray has a market capitalization of $390.72 million and generates $87.78 million in revenue each year. The company earns $-120,200,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. View additional information about Viewray.

What is Viewray's official website?

The official website for Viewray is http://www.viewray.com/.

How can I contact Viewray?

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]

This page was last updated on 4/10/2020 by MarketBeat.com Staff